94 related articles for article (PubMed ID: 26822567)
1. Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins.
Gazzano E; Chegaev K; Rolando B; Blangetti M; Annaratone L; Ghigo D; Fruttero R; Riganti C
Bioorg Med Chem; 2016 Mar; 24(5):967-75. PubMed ID: 26822567
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance.
Riganti C; Rolando B; Kopecka J; Campia I; Chegaev K; Lazzarato L; Federico A; Fruttero R; Ghigo D
Mol Pharm; 2013 Jan; 10(1):161-74. PubMed ID: 23186264
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux.
Riganti C; Miraglia E; Viarisio D; Costamagna C; Pescarmona G; Ghigo D; Bosia A
Cancer Res; 2005 Jan; 65(2):516-25. PubMed ID: 15695394
[TBL] [Abstract][Full Text] [Related]
4. H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance.
Chegaev K; Rolando B; Cortese D; Gazzano E; Buondonno I; Lazzarato L; Fanelli M; Hattinger CM; Serra M; Riganti C; Fruttero R; Ghigo D; Gasco A
J Med Chem; 2016 May; 59(10):4881-9. PubMed ID: 27120394
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide releasing acridone carboxamide derivatives as reverters of doxorubicin resistance in MCF7/Dx cancer cells.
Rajendra Prasad VV; Deepak Reddy G; Kathmann I; Amareswararao M; Peters GJ
Bioorg Chem; 2016 Feb; 64():51-8. PubMed ID: 26657603
[TBL] [Abstract][Full Text] [Related]
6. RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells.
Doublier S; Riganti C; Voena C; Costamagna C; Aldieri E; Pescarmona G; Ghigo D; Bosia A
Mol Cancer Res; 2008 Oct; 6(10):1607-20. PubMed ID: 18922976
[TBL] [Abstract][Full Text] [Related]
7. iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells.
De Boo S; Kopecka J; Brusa D; Gazzano E; Matera L; Ghigo D; Bosia A; Riganti C
Mol Cancer; 2009 Nov; 8():108. PubMed ID: 19925669
[TBL] [Abstract][Full Text] [Related]
8. Na+/H+ exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin.
Miraglia E; Viarisio D; Riganti C; Costamagna C; Ghigo D; Bosia A
Int J Cancer; 2005 Jul; 115(6):924-9. PubMed ID: 15729714
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells.
Kopecka J; Campia I; Brusa D; Doublier S; Matera L; Ghigo D; Bosia A; Riganti C
J Cell Mol Med; 2011 Jul; 15(7):1492-504. PubMed ID: 20716130
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of sphingolipids in MRP1 overexpressing HT29 cells.
Kok JW; Veldman RJ; Klappe K; Koning H; Filipeanu CM; Müller M
Int J Cancer; 2000 Jul; 87(2):172-8. PubMed ID: 10861470
[TBL] [Abstract][Full Text] [Related]
11. Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells.
Meschini S; Calcabrini A; Monti E; Del Bufalo D; Stringaro A; Dolfini E; Arancia G
Int J Cancer; 2000 Sep; 87(5):615-28. PubMed ID: 10925353
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity.
Chegaev K; Riganti C; Lazzarato L; Rolando B; Guglielmo S; Campia I; Fruttero R; Bosia A; Gasco A
ACS Med Chem Lett; 2011 Jul; 2(7):494-7. PubMed ID: 24900337
[TBL] [Abstract][Full Text] [Related]
13. Pyruvate Treatment Restores the Effectiveness of Chemotherapeutic Agents in Human Colon Adenocarcinoma and Pleural Mesothelioma Cells.
Mungo E; Bergandi L; Salaroglio IC; Doublier S
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30423827
[TBL] [Abstract][Full Text] [Related]
14. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
Wang Z; Yang L; Xia Y; Guo C; Kong L
Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide suppresses apoptosis in human colon cancer cells by scavenging mitochondrial superoxide anions.
Wenzel U; Kuntz S; De Sousa UJ; Daniel H
Int J Cancer; 2003 Sep; 106(5):666-75. PubMed ID: 12866025
[TBL] [Abstract][Full Text] [Related]
16. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells.
Riganti C; Voena C; Kopecka J; Corsetto PA; Montorfano G; Enrico E; Costamagna C; Rizzo AM; Ghigo D; Bosia A
Mol Pharm; 2011 Jun; 8(3):683-700. PubMed ID: 21491921
[TBL] [Abstract][Full Text] [Related]
17. Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells.
Riganti C; Doublier S; Costamagna C; Aldieri E; Pescarmona G; Ghigo D; Bosia A
Mol Pharmacol; 2008 Aug; 74(2):476-84. PubMed ID: 18463201
[TBL] [Abstract][Full Text] [Related]
18. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
[TBL] [Abstract][Full Text] [Related]
19. Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein.
Riganti C; Gazzano E; Gulino GR; Volante M; Ghigo D; Kopecka J
Cancer Lett; 2015 May; 360(2):219-26. PubMed ID: 25681670
[TBL] [Abstract][Full Text] [Related]
20. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
